Roth/MKM initiates Coya Therapeutics stock with buy rating

Roth/MKM initiated Coya Therapeutics at Buy with a $12 target versus a $4.87 share price, implying roughly 146% upside; consensus targets are even higher at $14-$18. The bullish case is supported by positive Phase 1 ALS data, FDA Fast Track designation for COYA 302, and modeled peak worldwide revenue of about $2.2 billion by 2040. Coya also reported about $51 million of cash at Q1 2026, enough to fund operations into 2H 2027, while leadership changes and patent protection through 2040 add to the strategic backdrop.

Analysis

COYA is a classic “data-to-designation” biotech where the first leg of rerating is already underway, but the bigger debate is whether the market is underwriting a binary proof-of-concept story or a multi-year platform value. Fast Track materially shortens the path to regulatory interaction and should improve partnering optionality, but it does not de-risk efficacy, dose selection, or trial execution; in small neuroinflammation programs, that gap between regulatory interest and clinical validation is where most of the upside evaporates.

The more interesting second-order effect is competitive positioning within ALS and adjacent neurodegeneration. If COYA 302 continues to show tolerability plus a biomarker signal, it could become a reference asset for other Treg-modulating or combination immunology programs, pulling capital toward the space and away from “single-mechanism, late-line” ALS shots on goal. Conversely, any incremental safety issue would likely compress the entire category’s multiple, because investors will assume the mechanism—not just the molecule—has a ceiling.

The market is probably pricing the possibility of a partnering event and eventual approval path, but not the capital intensity required to bridge the next 18–24 months. Even with a healthy balance sheet, a Phase 2 readout that requires expansion or confirmatory work can quickly bring dilution risk back into focus, especially for a sub-$200M name where each financing round can reset upside math. That makes the timing asymmetry important: near-term sentiment can stay strong for months, while the real inflection is the next clinical dataset, not the current coverage initiation.

The contrarian read is that the stock may still be undervalued if the platform generalizes beyond ALS into FTD, because the addressable commercial story becomes less about one orphan indication and more about a multi-program immunology franchise. But if investors are paying for 2040 revenue visibility today, the stock becomes very sensitive to any slippage in trial cadence; at that point the setup shifts from “discovery” to “financing and execution.”

Key Decisions for Investors

• Long COYA on pullbacks into the next clinical catalyst; best risk/reward is pre-Phase 2 data if implied dilution risk is not yet fully priced. Use a hard stop on a failed efficacy read because downside can re-rate sharply when mechanism confidence breaks.
• Buy COYA call spreads 6-12 months out to express upside to a partnering or positive interim-data event while limiting premium burn. Favor strikes that target a 1.5-2.0x move from spot rather than deep OTM lottery exposure.
• Pair trade: long COYA / short a basket of higher-burn, late-stage neurodegeneration names with weaker balance sheets. The thesis is that capital will reward earlier, biomarker-driven programs with cleaner financing runway over crowded, capital-intensive peers.
• If COYA rallies into a financing window, trim into strength rather than chase. In sub-$200M biotech, the market often discounts the next raise before management does; preserve dry powder for post-offer weakness.
• Monitor for a partnering announcement or expanded dataset as the key medium-term catalyst; if neither arrives by the expected runway window, reassess because execution risk rises materially into 2H27.